Fingolimod hydrochloride
Based on 77 publication(s) in Google Scholar
Fingolimod (FTY720) hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride is also a pak1 activator and immunosuppressant.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 162359-56-0
- Formula: C19H34ClNO2
- Molecular Weight:343.93
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Anti-COVID-19 Compound Library
HY-L052
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Neuroprotective Compound Library
HY-L070
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Cardiotoxic Compound Library
HY-L225
-
RNA Binding Bioactive Compound Library
HY-L248
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Fingolimod hydrochloride
More- Signal Transduct Target Ther. 2025 Mar 24;10(1):101. [Abstract]
- Nature. 2025 Nov;647(8090):706-715. [Abstract]
- Cancer Cell. 2025 Feb 10;43(2):213-231.e9. [Abstract]
- Cell Metab. 2025 Oct 24:S1550-4131(25)00395-X. [Abstract]
- Nat Genet. 2025 Dec;57(12):3050-3065. [Abstract]
- Immunity. 2024 Feb 13;57(2):364-378.e9. [Abstract]
- Cell Res. 2022 May;32(5):477-490. [Abstract]
- Cancer Res. 2026 Mar 5. [Abstract]
- Nat Commun. 2024 Sep 8;15(1):7850. [Abstract]
- Nat Commun. 2024 May 31;15(1):4665. [Abstract]
- Nat Commun. 2024 Jun 13;15(1):5056. [Abstract]
- Nat Commun. 2022 Jan 10;13(1):182. [Abstract]
- Autophagy. 2024 Nov;20(11):2490-2510. [Abstract]
- Adv Sci (Weinh). 2025 Aug 30:e07330. [Abstract]
- Adv Sci (Weinh). 2024 Jul 23:e2404080. [Abstract]
- Cardiovasc Res. 2025 Nov 11:cvaf215. [Abstract]
- Theranostics. 2021 Jan 1;11(1):117-131. [Abstract]
- Hum Reprod Open. 2025 May 14;2025(3):hoaf027. [Abstract]
- Nat Cardiovasc Res. 2025 Feb;4(2):216-234. [Abstract]
- Research (Wash D C). 2025 Apr 15:8:0662. [Abstract]
- J Immunother Cancer. 2026 Mar 27;14(3):e012460. [Abstract]
- J Immunother Cancer. 2025 Jul 15;13(7):e010926. [Abstract]
- J Immunother Cancer. 2025 Feb 6;13(2):e010150. [Abstract]
- Cell Rep Med. 2024 Jun 18;5(6):101590. [Abstract]
- Cancer Lett. 2026 Apr 10:643:218283. [Abstract]
- Cancer Lett. 2018 Nov 1:436:75-86. [Abstract]
- Cell Death Dis. 2025 Jan 20;16(1):31. [Abstract]
- Phytomedicine. 2025 Sep 19:148:157271. [Abstract]
- Phytomedicine. 2025 May 30:144:156917. [Abstract]
- Phytomedicine. 2025 May 27:143:156919. [Abstract]
- Haematologica. 2020 Mar;105(3):674-686. [Abstract]
- J Med Chem. 2025 Oct 17. [Abstract]
- J Med Chem. 2025 Apr 17. [Abstract]
- Breast Cancer Res. 2017 Aug 4;19(1):90. [Abstract]
- Cancer Immunol Immunother. 2025 Oct 6;74(11):326. [Abstract]
- Cancer Immunol Immunother. 2025 Mar 25;74(5):161. [Abstract]
- Commun Biol. 2021 Mar 25;4(1):399. [Abstract]
- Life Sci. 2019 Jan 15:217:243-250. [Abstract]
- Biomolecules. 2026 Feb 20;16(2):328. [Abstract]
- Front Pharmacol. 2018 Oct 31:9:1237. [Abstract]
- Int Immunopharmacol. 2025 Mar 22:153:114495. [Abstract]
- Int Immunopharmacol. 2024 Oct 31;143(Pt 3):113526. [Abstract]
- Bioorg Chem. 2024 Jun:147:107412. [Abstract]
- Am J Physiol Cell Physiol. 2023 Nov 1;325(5):C1354-C1368. [Abstract]
- Eur J Pharmacol. 2022 Oct 15:933:175271. [Abstract]
- J Mol Cell Cardiol. 2022 Mar:164:110-125. [Abstract]
- Int Immunopharmacol. 2021 Jul:96:107511. [Abstract]
- RSC Adv. 2024 Jul 12;14(30):22044-22055. [Abstract]
- Front Endocrinol. 2018 Mar 22:9:120. [Abstract]
- Mol Neurobiol. 2024 Apr;61(4):1936-1952. [Abstract]
- Helicobacter. 2019 Oct;24(5):e12652. [Abstract]
- BMC Microbiol. 2025 May 16;25(1):299. [Abstract]
- FASEB J. 2024 Jan 31;38(2):e23417. [Abstract]
- J Inflamm Res. 2025 Feb 14:18:2229-2245. [Abstract]
- J Pharmacol Exp Ther. 2026 Apr;393(4):104306. [Abstract]
- Cell Signal. 2025 Apr 15:132:111807. [Abstract]
- Mol Hum Reprod. 2026 Feb 16:gaag009. [Abstract]
- Reprod Biomed Online. 2023 Nov;47(5):103304. [Abstract]
- J Immunol. 2024 Nov 15;213(10):1499-1507. [Abstract]
- Wound Repair Regen. 2023 Jul-Aug;31(4):489-499. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- J Gastroenterol Hepatol. 2018 Jan 15. [Abstract]
- Clin Rheumatol. 2026 Mar;45(3):1709-1720. [Abstract]
- J Integr Neurosci. 2024 Aug 12;23(8):142. [Abstract]
- Vet Microbiol. 2021 Oct:261:109177. [Abstract]
- Curr Eye Res. 2024 Aug;49(8):862-871. [Abstract]
- BMC Res Notes. 2026 Jan 23;19(1):75. [Abstract]
- Biomed Chromatogr. 2024 Jun 26:e5947. [Abstract]
- Res Sq. 2026 Jun 2.
- bioRxiv. 2026 Mar 17:2026.03.10.710574. [Abstract]
- bioRxiv. 2026 Jan 8:2026.01.07.698231. [Abstract]
- Res Sq. 2024 Oct 18.
- Research Square Preprint. 2024 Apr 23.
- Research Square Preprint. 2023 Dec 1.
- Research Square Preprint. 2023 Sep 6.
- J Immunol Sci. March 31, 2022.
- Patent. US20210393524A1.
Customer Validation & Images
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
-
Flow Cytometry
-
Histological Imaging/Staining
-
Cell Proliferation/Viability Assay
Biological Activity
|
S1P 0.033 nM (IC50, in K562 and NK cells) |
PAK1 |
Fingolimod hydrochloride (FTY720) is a S1P antagonist with an IC50 of 0.033 nM in K562 and NK cells[1].
The monocyte-derived immature dendritic cells (iDCs) are pretreated with various concentrations of S1P for various periods of time prior to their incubation with NK cells. Four hours incubation of autologous or allogeneic iDCs with 0.2-20 μM of S1P significantly protectes these cells from NK cell lysis. The IC50 values of S1P are calculated at 160 nM for autologous iDCs, and 34 nM for allogeneic iDCs. Next, the inhibitory effect of S1P is revered by various concentrations of Fingolimod hydrochloride (FTY720) or SEW2871, with an IC50 effect of 173 or 15 nM, respectively[1].
FTY720 enhances serum S1P levels by inhibiting S1P lyase activity[2].
The number of Iba1+ cells in ipsilateral CA3 is counted, and the corresponding graph shows a significantly lower number of Iba1+ cells in CA3 of the Kainic acid (KA)+FTY720 group than in CA3 of KA group[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
FTY720 attenuates microgliosis, modulates the microglia inflammatory phenotype by reducing LPS-mediated activation of p38 MAPK signalling pathway. Thus, FTY720 shares both direct neuroprotective and anti-inflammatory properties that can contribute to overall neuroprotection. In particular, the potential of FTY720 to switch microglia phenotype from a detrimental to a protective one represents a therapeutic mechanism for attenuating acute and chronic CNS damage[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 162359-56-0
-
Appearance Solid
-
Molecular Weight 343.93
-
Formula C19H34ClNO2
-
Color White to off-white
-
SMILES
OCC(N)(CO)CCC1=CC=C(C=C1)CCCCCCCC.[H]Cl
-
Synonyms
FTY720
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (77)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy. [Abstract]2025 Mar 24;10(1):101. PMID: 40122855 -
Nature
2025 Nov;647(8090):706-715. PMID: 41034585 -
Cancer Cell
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. [Abstract]2025 Feb 10;43(2):213-231.e9. PMID: 39729997 -
Cell Metab
Quercetin-derived microbial metabolite DOPAC potentiates CD8+ T cell anti-tumor immunity via NRF2-mediated mitophagy. [Abstract]2025 Oct 24:S1550-4131(25)00395-X. PMID: 41138722 -
Nat Genet
TGF-β builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages. [Abstract]2025 Dec;57(12):3050-3065. PMID: 41203813 -
Immunity
Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response. [Abstract]2024 Feb 13;57(2):364-378.e9. PMID: 38301651
Fingolimod hydrochloride purchased from MedChemExpress. Usage Cited in: Immunity. 2024 Feb 13;57(2):364-378.e9. [Abstract]
Dynamic changes in blood leukocytes and neutrophils upon Firategrast (0.2 mg/kg; i.p.) or vehicle treatment expressed as percentage of the mean cell count at baseline.
-
Cell Res
2022 May;32(5):477-490. PMID: 35105939 -
Cancer Res
Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity. [Abstract]2026 Mar 5. PMID: 41784618 -
Nat Commun
TCF-1 and TOX regulate the memory formation of intestinal group 2 innate lymphoid cells in asthma. [Abstract]2024 Sep 8;15(1):7850. PMID: 39245681 -
Nat Commun
Glycolysis inhibition induces anti-tumor central memory CD8+T cell differentiation upon combination with microwave ablation therapy. [Abstract]2024 May 31;15(1):4665. PMID: 38821965 -
Nat Commun
2024 Jun 13;15(1):5056. PMID: 38871792 -
Nat Commun
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. [Abstract]2022 Jan 10;13(1):182. PMID: 35013322 -
Autophagy
Metabolic stress induces a double-positive feedback loop between AMPK and SQSTM1/p62 conferring dual activation of AMPK and NFE2L2/NRF2 to synergize antioxidant defense. [Abstract]2024 Nov;20(11):2490-2510. PMID: 38953310 -
Adv Sci (Weinh)
Dnmt1 Alleviates S1PR1-Mediated Pyroptosis after Spinal Cord Injury through Regulating Pon3 Expression. [Abstract]2025 Aug 30:e07330. PMID: 40884250 -
Adv Sci (Weinh)
PP2Ac Regulates Autophagy via Mediating mTORC1 and ULK1 During Osteoclastogenesis in the Subchondral Bone of Osteoarthritis. [Abstract]2024 Jul 23:e2404080. PMID: 39041921 -
Cardiovasc Res
Periaortic lymphatic vessels protect against thoracic aortic dissection through mobilizing immune response. [Abstract]2025 Nov 11:cvaf215. PMID: 41213294 -
Theranostics
Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A. [Abstract]2021 Jan 1;11(1):117-131. PMID: 33391465 -
Hum Reprod Open
Hypoxia exposure impairs male fertility via inhibiting Septin2-mediated spermatogonial proliferation. [Abstract]2025 May 14;2025(3):hoaf027. PMID: 40487848
Fingolimod hydrochloride purchased from MedChemExpress. Usage Cited in: Hum Reprod Open. 2025 May 14;2025(3):hoaf027. [Abstract]
Treatment with Fingolimod (FTY720) (2 mg/kg;i.p.; once daily for 35 days) exacerbated the negative impact of hypoxia on fertility in male mice, as evidenced by worsened seminiferous epithelium.
Fingolimod hydrochloride purchased from MedChemExpress. Usage Cited in: Hum Reprod Open. 2025 May 14;2025(3):hoaf027. [Abstract]
Fingolimod (FTY720) (2 mg/kg;i.p.; once daily for 35 days) significantly reduced sperm count and motility and increased sperm deformity rate in hypoxic mice.
-
Nat Cardiovasc Res
2025 Feb;4(2):216-234. PMID: 39953275 -
Research (Wash D C)
Early Growth Response Gene 1 Benefits Autoimmune Disease by Promoting Regulatory T Cell Differentiation as a Regulator of Foxp3. [Abstract]2025 Apr 15:8:0662. PMID: 40235598
Fingolimod hydrochloride purchased from MedChemExpress. Usage Cited in: Research (Wash D C). 2025 Apr 15:8:0662. [Abstract]
Fingolimod (FTY-720) (1 mg/kg) apparently elevated the ratio of CD4+Egr-1+ cells in lymph nodes of EAE mice.
Fingolimod hydrochloride purchased from MedChemExpress. Usage Cited in: Research (Wash D C). 2025 Apr 15:8:0662. [Abstract]
H&E and LFB staining showed inflammatory infiltration in the spinal cord. Fingolimod (FTY-720) (1 mg/kg) alleviated spinal cord inflammatory infiltration and demyelination in ERE-EGFP mice with EAE.
-
J Immunother Cancer
Liver-directed AAV-IL-10 therapy enhances CD8+ T cell-mediated immunity against hepatocellular carcinoma. [Abstract]2026 Mar 27;14(3):e012460. PMID: 41895716 -
J Immunother Cancer
Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion. [Abstract]2025 Jul 15;13(7):e010926. PMID: 40664443 -
J Immunother Cancer
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens. [Abstract]2025 Feb 6;13(2):e010150. PMID: 39915006 -
Cell Rep Med
Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement. [Abstract]2024 Jun 18;5(6):101590. PMID: 38843844 -
Cancer Lett
2026 Apr 10:643:218283. PMID: 41651398 -
Cancer Lett
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer. [Abstract]2018 Nov 1:436:75-86. PMID: 30120964
Fingolimod hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Nov 1:436:75-86. [Abstract]
Immunoblotsof sphingolipid metabolizing enzymes SPHK1, SPHK2, acid ceramidase (AC), and glucosylceramide synthase (GCS) in A2780. cp20, SKOV3. TR, HeyA8. MDR, COV362, and CAOV3 cell lines exposed to the indicated concentrations of FTY720 (FTY) or DMSO (VC) for 24 h.
Fingolimod hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Nov 1:436:75-86. [Abstract]
FTY720+ICI 47699 and FTY720+NSC 241240 increase apoptosis marker, cleaved caspase 3 in a PDX model of EOC. IHC of tumor sections is used to detect the apoptosis marker cleaved caspase 3 and the cell cycle inhibitor p21.
-
Cell Death Dis
S1PR3-driven positive feedback loop sustains STAT3 activation and keratinocyte hyperproliferation in psoriasis. [Abstract]2025 Jan 20;16(1):31. PMID: 39833165 -
Phytomedicine
Alisol A 24-acetate protects against NASH-associated fibrosis via suppression of Kupffer cell-derived SPHK1/S1P axis. [Abstract]2025 Sep 19:148:157271. PMID: 40992063 -
Phytomedicine
Ginsenoside F2-modified liposomes delivering FTY720 enhance glioblastoma targeting and antitumor activity via ferroptosis. [Abstract]2025 May 30:144:156917. PMID: 40480023 -
Phytomedicine
Unveiling XinJia-LuHuang Granules' protective mechanism against atherosclerosis: Integrating network pharmacology, metabolomics, and experimental validation. [Abstract]2025 May 27:143:156919. PMID: 40466509 -
Haematologica
2020 Mar;105(3):674-686. PMID: 31289206 -
J Med Chem
Systems Biology-Based Drug Repositioning Identifies Extracellular Matrix Module as a Therapeutic Target in Lung Squamous Cell Carcinoma. [Abstract]2025 Oct 17. PMID: 41105954 -
J Med Chem
A Novel Compound 3a-M1, from Metabolites of Sinomenine Derivative 3a, Exerts Potent Anti-Aplastic Anemia Activity via IP3R/ORAI-Mediated CTL Ferroptosis. [Abstract]2025 Apr 17. PMID: 40243551 -
Breast Cancer Res
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. [Abstract]2017 Aug 4;19(1):90. PMID: 28778177
Fingolimod hydrochloride purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2017 Aug 4;19(1):90. [Abstract]
The effect of ZD1839-FTY720 treatment on CD44 expression in TNBC cell lines. HCC1806, Hs578T, and MDA-MB-468 TNBC cell lines at ~40% confluence in 12-well plates are exposed for 24 h to ZD1839 (Gef: 0.1 to 10 μM), with or without the addition of 1.5 μM FTY720.
-
Cancer Immunol Immunother
Tumor-draining lymph nodes respond to immune checkpoint inhibition and orchestrate tumor immune remodeling. [Abstract]2025 Oct 6;74(11):326. PMID: 41051631 -
Cancer Immunol Immunother
Microwave ablation combined with immune checkpoint inhibitor enhanced the antitumor immune activation and memory in rechallenged tumor mouse model. [Abstract]2025 Mar 25;74(5):161. PMID: 40131498 -
Commun Biol
A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells. [Abstract]2021 Mar 25;4(1):399. PMID: 33767353 -
Life Sci
FTY720 inhibits the activation of pancreatic stellate cells by promoting apoptosis and suppressing autophagy via the AMPK/mTOR pathway. [Abstract]2019 Jan 15:217:243-250. PMID: 30550889 -
Biomolecules
Notch Signaling Exacerbates Pulmonary Fibrosis by Regulating the Differentiation of CD4+ Tissue-Resident Memory T Cells. [Abstract]2026 Feb 20;16(2):328. PMID: 41750395 -
Front Pharmacol
Pien Tze Huang Alleviates Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Mice by Regulating Th1 and Th17 Cells. [Abstract]2018 Oct 31:9:1237. PMID: 30429789 -
Int Immunopharmacol
FTY720 alleviates HBV-mediated inflammatory liver injury through a dual role of inhibiting lymphocyte trafficking and viral replication. [Abstract]2025 Mar 22:153:114495. PMID: 40121743 -
Int Immunopharmacol
CD83 mediates the inhibitory effect of the S1PR1 agonist CYM5442 on LPS-induced M1 polarization of macrophages through the ERK-STAT-1 signaling pathway. [Abstract]2024 Oct 31;143(Pt 3):113526. PMID: 39486189 -
Bioorg Chem
Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies. [Abstract]2024 Jun:147:107412. PMID: 38696845 -
Am J Physiol Cell Physiol
Glycolytic enzyme PFKFB3 regulates sphingosinae 1-phosphate receptor 1 in proangiogenic glomerular endothelial cells under diabetic condition. [Abstract]2023 Nov 1;325(5):C1354-C1368. PMID: 37781737 -
Eur J Pharmacol
Geniposide inhibits SphK1 membrane targeting to restore macrophage polarization balance in collagen-induced arthritis mice. [Abstract]2022 Oct 15:933:175271. PMID: 36108735 -
J Mol Cell Cardiol
Ventricular SK2 upregulation following angiotensin II challenge: Modulation by p21-activated kinase-1. [Abstract]2022 Mar:164:110-125. PMID: 34774547 -
Int Immunopharmacol
Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells. [Abstract]2021 Jul:96:107511. PMID: 33915521 -
RSC Adv
Carboxymethylcellulose encapsulated fingolimod, siRNA@ZnO hybrid nanocomposite as a new anti-Alzheimer's material. [Abstract]2024 Jul 12;14(30):22044-22055. PMID: 39006767 -
Front Endocrinol
Nuclear Insulin-Like Growth Factor Binding Protein-3 As a Biomarker in Triple-Negative Breast Cancer Xenograft Tumors: Effect of Targeted Therapy and Comparison With Chemotherapy. [Abstract]2018 Mar 22:9:120. PMID: 29623068 -
Mol Neurobiol
Teriflunomide Promotes Blood-Brain Barrier Integrity by Upregulating Claudin-1 via the Wnt/β-catenin Signaling Pathway in Multiple Sclerosis. [Abstract]2024 Apr;61(4):1936-1952. PMID: 37819429 -
Helicobacter
Vaccine-induced gastric CD4+ tissue-resident memory T cells proliferate in situ to amplify immune response against Helicobacter pylori insult. [Abstract]2019 Oct;24(5):e12652. PMID: 31414552 -
BMC Microbiol
Fingolimod as a potent anti-Staphylococcus aureus: pH-dependent cell envelope damage and eradication of biofilms/persisters. [Abstract]2025 May 16;25(1):299. PMID: 40380090 -
FASEB J
SPHK1/S1P/S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial-mesenchymal transition. [Abstract]2024 Jan 31;38(2):e23417. PMID: 38226856 -
J Inflamm Res
Fingolimod Suppresses NLRP3 Inflammasome Activation and Alleviates Oxidative Stress in Traumatic Brain Injury-Induced Acute Lung Injury. [Abstract]2025 Feb 14:18:2229-2245. PMID: 39974815 -
J Pharmacol Exp Ther
Targeting cholangiocyte sphingosine-1-phosphate (S1P) receptor 1 signaling alleviates cholestatic liver injury: Mechanistic insight into S1P/phosphorylated signal transducer and activator of transcription 3 axis. [Abstract]2026 Apr;393(4):104306. PMID: 41818851 -
Cell Signal
2025 Apr 15:132:111807. PMID: 40239727 -
Mol Hum Reprod
Stage-dependent sphingosine-1-phosphate pathway modulation as a therapeutic strategy in a murine model of adenomyosis. [Abstract]2026 Feb 16:gaag009. PMID: 41698850 -
Reprod Biomed Online
Blocking sphingosine 1-phosphate receptor 1 with modulators reduces immune cells infiltration and alleviates endometriosis in mice. [Abstract]2023 Nov;47(5):103304. PMID: 37757611 -
J Immunol
Hepatitis B Virus Increases SphK1-S1P Synthesis by Promoting the Availability of the Transcription Factor USF1. [Abstract]2024 Nov 15;213(10):1499-1507. PMID: 39400236 -
Wound Repair Regen
Drug suspending during wound healing effectively weakens immunosuppression-related complications by preserving CD8+ T cell function. [Abstract]2023 Jul-Aug;31(4):489-499. PMID: 37129099 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
J Gastroenterol Hepatol
Amelioration of colitis through blocking lymphocytes entry to Peyer's patches by sphingosine-1-phosphate lyase inhibitor. [Abstract]2018 Jan 15. PMID: 29336057 -
Clin Rheumatol
PP2A dysfunction mediated by PPP2R1A deficiency drives cGAS-STING-dependent hyperinflammation in SLE CD14+ monocytes. [Abstract]2026 Mar;45(3):1709-1720. PMID: 41582267 -
J Integr Neurosci
Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway. [Abstract]2024 Aug 12;23(8):142. PMID: 39207074 -
Vet Microbiol
Lipid metabolism is a novel and practical source of potential targets for antiviral discovery against porcine parvovirus. [Abstract]2021 Oct:261:109177. PMID: 34391196 -
Curr Eye Res
FTY720 Suppresses Pathogenic Retinal Müller Cell Activation and Chronic Progression by Inhibiting the mTOR/NF-κB Signaling Pathway and Regulating Autophagy. [Abstract]2024 Aug;49(8):862-871. PMID: 38577836 -
BMC Res Notes
A genome-wide CRISPR/Cas9 screen reveals novel positive regulators of FTY720 sensitivity in acute lymphoblastic leukemia cells. [Abstract]2026 Jan 23;19(1):75. PMID: 41578398 -
Biomed Chromatogr
Liquid chromatography-tandem mass spectrometry for determination of fingolimod and its active metabolite fingolimod phosphate in whole blood of patients with multiple sclerosis. [Abstract]2024 Jun 26:e5947. PMID: 38932506 -
-
bioRxiv
Therapeutic scheduling of WEE1 inhibition preserves T cell function and promotes immune control of HPV+ tumors. [Abstract]2026 Mar 17:2026.03.10.710574. PMID: 41889874 -
bioRxiv
Indomethacin exerts both cyclooxygenase inhibition-dependent and independent mechanisms to enhance chemo-immunotherapy in mice. [Abstract]2026 Jan 8:2026.01.07.698231. PMID: 41542639 -
-
-
-
-
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (290.76 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 100 mg/mL (290.76 mM; Need ultrasonic)
H2O : 50 mg/mL (145.38 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
Immature dendritic cells (DCs) are left intact or are incubated with 2 μM S1P, 10 nM Fingolimod hydrochloride, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 h. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2×105 cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
This study is carried out on 2-month-old male C57BL/6J mice or sphingosine kinase-2 deficient (SPHK-2-/-) mice weighing 25-30 g, receiving a standard diet and water ad libitum. C57BL/6J wild-type or SPHK-2-/- mice receives i.p.-injections of LPS (9 mg/kg)/PepG (1 mg/kg) or its vehicle (0.9% saline). Sham mice are not subjected to LPS/PepG, but are otherwise treated in the same way. At 1 h after LPS/PepG challenge, mice are treated with Fingolimod hydrochloride (0.1 mg/kg i.v.) or its vehicle (10% DMSO). To elucidate the role of different S1P receptors in the observed effects of Fingolimod hydrochloride, mice receive (45 min after LPS/PepG and 15 min prior to Fingolimod hydrochloride) the selective PI3K inhibitor LY294002 (0.3 mg/kg i.v.) or the selective S1P2 receptor antagonist JTE 013 (1 mg/kg i.v.) or (1 h after LPS/PepG) the selective S1P1 receptor agonist SEW2871 (1 mg/kg i.v.) or vehicle (10% DMSO).
Rat[3]
The Sprague-Dawley rats (200 to 250 g) are used. Fingolimod hydrochloride is applied icv (1 μg/2 μL), together with Kainic acid (KA), plus intraperitoneally (ip; 1 mg/kg) 24 h before, and daily, until sacrifice 3 days aftericv. Rats are evaluated for neurological score, neuronal loss in CA3 hippocampal region and activation of microglia at the lesion site.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rolin J, et al. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol Immunother. 2010, 59(4), 575-586. [Content Brief]
[2]. Coldewey SM, et al. Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis. Sci Rep. 2016 Jun 9;6:27594. [Content Brief]
[3]. Cipriani R, et al. FTY720 attenuates excitotoxicity and neuroinflammation. J Neuroinflammation. 2015 May 8;12:86. [Content Brief]
[4]. Arielle M Bryan, et al. Sphingosine-1-phosphate receptors and innate immunity. Cell Microbiol. 2018 May;20(5):e12836. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO / Ethanol | 1 mM | 2.9076 mL | 14.5378 mL | 29.0757 mL | 72.6892 mL |
| 5 mM | 0.5815 mL | 2.9076 mL | 5.8151 mL | 14.5378 mL | |
| 10 mM | 0.2908 mL | 1.4538 mL | 2.9076 mL | 7.2689 mL | |
| 15 mM | 0.1938 mL | 0.9692 mL | 1.9384 mL | 4.8459 mL | |
| 20 mM | 0.1454 mL | 0.7269 mL | 1.4538 mL | 3.6345 mL | |
| 25 mM | 0.1163 mL | 0.5815 mL | 1.1630 mL | 2.9076 mL | |
| 30 mM | 0.0969 mL | 0.4846 mL | 0.9692 mL | 2.4230 mL | |
| 40 mM | 0.0727 mL | 0.3634 mL | 0.7269 mL | 1.8172 mL | |
| 50 mM | 0.0582 mL | 0.2908 mL | 0.5815 mL | 1.4538 mL | |
| 60 mM | 0.0485 mL | 0.2423 mL | 0.4846 mL | 1.2115 mL | |
| 80 mM | 0.0363 mL | 0.1817 mL | 0.3634 mL | 0.9086 mL | |
| 100 mM | 0.0291 mL | 0.1454 mL | 0.2908 mL | 0.7269 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz